DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 03 · Volume 35 · May 2002 DOI: 10.1055/s-002-1964

Review

  • 83
    Brieden, T.; Ujeyl, M.; Naber, D.:

    Psychopharmacological Treatment of Aggression in Schizophrenic Patients

    • Original Paper

  • 90
    Henning, U.; Löffler, S.; Krieger, K.; Klimke, A.:

    Uptake of Clozapine into HL-60 Promyelocytic Leukaemia Cells

  • 96
    Eschweiler, G. W.; Bartels, M.; Längle, G.; Wild, B.; Gaertner, I.; Nickola, M.:

    Heart-Rate Variability (HRV) in the ECG Trace of Routine EEGs: Fast Monitoring for the Anticholinergic Effects of Clozapine and Olanzapine?

  • 101
    Buchberger, R.; Wagner, W.:

    Fluvoxamine: Safety Profile in Extensive Post-Marketing Surveillance

    • Case Report

  • 109
    Wetter, T. C.; Brunner, J.; Bronisch, T.:

    Restless Legs Syndrome Probably Induced by Risperidone Treatment

  • 112
    Azaz-Livshits, T.; Hershko, A.; Ben-Chetrit, E.:

    Paroxetine Associated Hepatotoxicity: A Report of 3 Cases and a Review of the Literature

  • 116
    Köhnke, M. D.; Griese, E.-U.; Stösser, D.; Gaertner, I.; Barth, G.:

    Cytochrome P450 2D6 Deficiency and its Clinical Relevance in a Patient Treated with Risperidone

  • 119
    Bottlender, R.; Jäger, M.; Hofschuster, E.; Dobmeier, P.; Möller, H.-J.:

    Neuroleptic Malignant Syndrome due to Atypical Neuroleptics: Three Episodes in One Patient

  • 122
    Mendhekar, D. N.; War, L.; Sharma, J. B.; Jiloha, R. C.:

    Olanzapine and Pregnancy

  • 124
    Virkkunen, M.; Wahlbeck, K.; Rissanen, A.; Naukkarinen, H.; Franssila-Kallunki, A.:

    Decrease of Energy Expenditure Causes Weight Increase in Olanzapine Treatment - A Case Study